It’s getting late on a Friday afternoon in early December.

Wall Street is already gone. The traders have their out-of-offices on. 

They're thinking about the weekend ski trip, untangling lights, the glass of wine with friends.

And while they're checked out, a small biotech most people have never heard of is about to release the most important data in its history.

The ticker is GPCR. Structure Therapeutics.

If you'd put $5,000 into that stock at Friday's close—and done absolutely nothing else—you'd have walked back into the market on Monday morning holding roughly $10,000. Maybe, as you’ll see, way more. 

All because of something that happened while you mowed the lawn in a pattern only you found impressive. (It was impressive.)

This actually happened with GPCR on Monday, December 8, 2025. 

It’s happened again and again with other stocks since. 

Today, allow me to show you exactly how that happened. 

And why it's going to keep happening—because it’s a reliable pattern. A pattern most investors catch too late.
In part because they’re not using AI in the right way. 

What Actually Happened 

Here's the timeline… 

On Sunday, December 7th, Structure Therapeutics put out a press release. Topline data from a mid-stage study of its experimental obesity pill, aleniglipron.

The numbers were good. At the top dose, patients lost 11.3% more weight than placebo over 36 weeks.

In a market obsessed with the next Ozempic, that's the kind of number that makes a portfolio manager forget he's on vacation.

But, of course, the market is closed on Sunday. Nobody could buy. Nobody could sell. All that demand just sat there, coiled, waiting for the opening bell.

Monday morning, the bell rang. And GPCR rocketed more than 100% higher in a single session.

Those positioned before the weekend caught the entire move. The people who read about it Monday afternoon caught nothing. 

They just watched.

The Monday Move

Here's the pattern…

A huge share of market-moving data doesn't drop during trading hours at all. It lands over the weekend. Friday nights. Sunday mornings. Before the Monday open.

There's a few reasons for that. 

Some of it is the calendar. Stuff happens on the weekends, too.

For example, the biggest conferences—where companies unveil their data to the world—tend to run on weekends. For biotech, it’s things like JPMorgan Healthcare in January. ASCO. ESMO.

The science gets presented Saturday and Sunday, so the news hits when the market is closed.

Another reason: the rules push that way. 

When news is material, the cleanest way to disclose it is to release it when the market's closed—so every investor gets the same chance to read it before anyone can trade. 

That's the orderly way. It's also where the gap gets made. 

The same thing drives "Merger Monday"—the deals get signed over the weekend and announced Sunday night, so the move lands at the open before anyone's watching. 

The calendar is full of these moments, clustered in the dead zone when most investors have stopped paying attention.

That's the inefficiency. The weekend is a blind spot. And blind spots are where the money is.

That’s Where AI Comes In

James has spent the last several months working with a patented artificial intelligence built to do one thing: scan the entire market for these setups before they happen. 

It surfaces the GPCRs before the Sunday press release, not after the Monday gap.

It’s not right every time. Nothing is. Some weekends the data disappoints and the stock falls. That's the deal you make with any catalyst trade. 

But the edge is real, because the inefficiency is real. 

Wall Street clocks out on Friday. The market’s most explosive setups often don’t.

This coming weekend, there's another setup the AI has flagged. 

James will walk you through it—the company, the catalyst, and exactly how to position before Friday's close.

Click here and he’ll show you everything.